Clayton Smiley, MD
Nephrology · Portland, ORNPI 1679544431
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.0%), education and food and beverage — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by AstraZeneca at 56.0% of the total. Reporting peaked in 2020 at $150 and has fallen 81.9% since, to $27 in 2023. That places this record below the midpoint for nephrology clinicians in OR, where the typical reported total is $249.
Across 12 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$150
- Otsuka America Pharmaceutical, Inc.$61
- Calliditas Therapeutics US Inc.$27
- Travere Therapeutics, Inc.$19
- Akebia Therapeutics Inc$10
Across 1 payment — averaging $23,924 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$24K
What the payments were for
- Speaking & faculty fees$15056%
- Food & beverage$104%
- Education$10840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $150 |
| Otsuka America Pharmaceutical, Inc. | 1 | $61 |
| Calliditas Therapeutics US Inc. | 2 | $27 |
| Travere Therapeutics, Inc. | 7 | $19 |
| Akebia Therapeutics Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ULTOMIRIS$150
How this compares
$268 in reported general payments places this provider in the 50th percentile of 120 nephrology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 49 | $168,721 |
| JardianceEmpagliflozin | 15 | $16,649 |
| Sevelamer Carbonate | 44 | $11,983 |
| Cinacalcet Hcl | 11 | $5,007 |
| Calcium Acetate | 51 | $4,874 |
| Potassium Citrate ErPotassium Citrate | 34 | $4,362 |
| Olmesartan Medoxomil | 151 | $3,282 |
| Torsemide | 87 | $2,869 |
| Potassium Chloride | 40 | $2,029 |
| Losartan Potassium | 147 | $1,845 |
| Amlodipine Besylate | 159 | $1,446 |
| Furosemide | 122 | $1,316 |
| Carvedilol | 99 | $1,220 |
| Eplerenone | 12 | $1,115 |
| Calcitriol | 67 | $1,094 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Portland
- Robert ProvenzanoPortland$45K
- Nayan AroraPortland$23K
- Rupali AvasarePortland$16K
- David EllisonPortland$12K
- Shehzad RehmanPortland$10K
- Arthur GreenbergPortland$7K
- Suzanne WatnickPortland$2K
- Hem DeodharPortland$1K
- Julia TankPortland$1K
- Chun Khai ChongPortland$956
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.